Antibiotic Resistance Market - By Disease (cUTI, cIAI, BSI), Pathogen (E. coli, K. pneumoniae), Drug Class (Oxazolidinones, Cephalosporin), Mechanism of Action (Cell Wall, Protein Synthesis Inhibitors), Distribution Channel, Global Forecast, 2023-2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAntibiotic Resistance Market Size
Antibiotic Resistance Market size is valued to be USD 8.2 billion in 2022 and is projected to grow at CAGR of 5.3% and reach USD 13.6 billion by 2032. Some of the major factors driving the growth of this market are increasing incidence of antibiotic resistant infections, growing need for new antibiotic therapies, increasing investment in antibiotic research and development, and increasing global public health concern and awareness.
Antibiotic resistance is an ability of bacteria or other microorganisms to resist the effects of antibiotics that were once effective in treating infections caused by them. This resistance develops when bacteria experience genetic alterations or mutations that enable them to survive and thrive even in the presence of antibiotics, reducing or eliminating the effectiveness of the medications. As a result, infections caused by these resistant bacteria become more difficult to treat, leading to prolonged illness, increased treatment costs, and potentially higher mortality rates.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Antibiotic Resistance Market Size in 2022 | USD 8.2 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 5.3% |
| 2032 Value Projection | USD 13.6 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 212 |
| Tables, Charts & Figures | 369 |
| Segments covered | Disease, Pathogen, Drug Class, Mechanism of Action, Distribution Channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
During the initial stages of the pandemic, there was an increased demand and use of antibiotics to treat secondary bacterial infections among the COVID-19 patients. The heightened use had potentially contribute to the development of antibiotic resistance. Further, the increased awareness among the public, healthcare professionals, and policymakers had resulted into a better understanding about the risks associated with antibiotic resistance and the need for adequate and responsible antibiotic usage.
The pandemic underscored the importance of antimicrobial stewardship programs, which promote the proper use of antibiotics and helping in overcoming the challenges caused by antibiotic resistant infections. Healthcare systems prioritized such programs to ensure that antibiotics are used only administered when required and with adequate doses to prevent the spread of drug-resistant infections. The pandemic increased public awareness of infectious diseases leading to better understanding of the consequences of antibiotic resistance and the importance of responsible antibiotic use. Overall, the pandemic had a positive impact on the global market demand.
Antibiotic Resistance Market Driving Factors
Antibiotic resistance is a huge problem that's getting worse. We need to tackle it from all anglesusing antibiotics wisely, stopping infections from spreading, finding new ways to fight bacteria, and coming up with better treatments. Bacteria like E. coli and Staphylococcus aureus are getting stronger against antibiotics, and more and more people are getting sick with these resistant infections. This is making the problem even bigger. As more people get sick, the demand for antibiotics goes up. This is driving the growth of the antibiotic market. Infections that people get in the hospital, often caused by drug-resistant bacteria, are driving up healthcare costs and making people sicker and even killing them. This shows how important it is to stop these infections from spreading.
Antibiotic Resistance Disease Market Analysis
Imagine you're having a problem with a stubborn infection. Antibiotics are like the weapons we use to fight these infections, but sometimes the germs become resistant to these weapons. This resistance can be different depending on the type of infection. For infections like those in your urinary tract or abdomen, the resistance challenge is quite high. Urinary tract infections alone account for nearly a quarter of the market for antibiotics to fight resistant infections. That's because more and more people are getting these complex urinary tract infections, and they often have other health issues like diabetes or kidney problems that make them more likely to develop these infections. Because these infections can be serious, people need antibiotics that can target a wide range of germs, including those that have become resistant.
Imagine you're at a marketplace filled with different types of medicines that fight bacteria and viruses. This marketplace is called the antibiotic resistance market. Inside this market, there are different sections based on the "bad guys" these medicines target, known as pathogens. Some of the most common pathogens have their own sections, such as E. coli, K. pneumoniae, and S. aureus. Among all the pathogens, E. coli has the biggest section. It was worth around 2.2 billion dollars back in 2022! K. pneumoniae comes in second place, taking up about 21.4% of the market. Why are these two pathogens so popular? Well, they're responsible for a lot of infections that are hard to treat with antibiotics. For example, the National Institutes of Health says that there are about 140,000 infections in the U.S. every year that are caused by bacteria like E. coli and K. pneumoniae. As time goes on, another pathogen called C. difficile is expected to become even more common. It's followed by P. aeruginosa, which is known for causing serious infections that can be costly to treat and can even be deadly.
Think of the antibiotic resistance market as a big pie. It's sliced up into different sections based on the types of drugs used to fight infections. These sections include oxazolidinones, cephalosporin, and others. The biggest slice of the pie belongs to oxazolidinones, which currently account for about 14%. They're expected to keep growing at a steady rate of 5.1% in the coming years. Oxazolidinones, especially Linezolid, are like super soldiers in the fight against bacteria. They're particularly effective against nasty bugs that are resistant to other antibiotics. Oxazolidinones don't kill bacteria outright; they stop them from multiplying. This is like putting the brakes on bacterial growth. Doctors often combine different antibiotics to create a stronger force against infections, and that's where the combination therapies segment comes in. It's expected to grow even faster, at a rate of 8%, because more and more bacteria are becoming resistant to single antibiotics.
Antibiotics work in different ways to kill or stop the growth of bacteria. Based on how they do this, we can divide the antibiotic resistance market into five main groupsCell wall synthesis inhibitorsThese antibiotics stop bacteria from building their cell walls, which are like the protective barriers around them. These drugs are very effective against a wide range of bacteria, both the common ones (Gram-positive) and some of the more resistant ones (Gram-negative). Because they work so well, doctors prescribe them a lot, and they made up the biggest part of the antibiotic resistance market in 2022, worth about 2.6 billion US dollars. Protein synthesis inhibitors These antibiotics target the bacteria's ability to make proteins, which are essential for their survival. DNA synthesis inhibitorsThese antibiotics mess with the bacteria's DNA, which is like their genetic blueprint. RNA synthesis inhibitors These antibiotics block the bacteria's ability to make RNA, which is another important molecule for them. Other mechanisms of action There are some antibiotics that don't fit into the other categories. They work in different ways to kill or stop the growth of bacteria. Out of these groups, RNA synthesis inhibitors are expected to grow the fastest in the coming years. This is because they work in a unique way by disrupting the process of making RNA, and they're effective against a wide range of bacteria.
When it comes to buying antibiotics, there are different ways to do it. You can go to a hospital, a regular pharmacy, or even order them online. In 2022, the most money was made from antibiotics sold at hospitals. That's because hospitals are where most people go when they need antibiotics for serious infections. Hospitals also have special programs to make sure that antibiotics are used properly and not too often. Online pharmacies are the fastest growing way to buy antibiotics. That's because they're convenient and easy to access. Some online pharmacies require a prescription to buy antibiotics, which helps reduce their overuse and misuse.
In 2022, the North American antibiotic resistance market is expected to reach USD 5.5 billion by 2032. The region has a relatively high prevalence of antibiotic resistant infections as the region has one of the highest rates of antibiotic consumption. Moreover, the increasing research and development activities related to antibiotics, increasing government support and fundings, and presence of key players operating in this market are expected to drive the growth of this market.
Antibiotic Resistance Market Share
The key players in the antibiotic resistance market are
- ACHAOGEN, INC.
- Basilea Pharmaceutica Ltd.
- MELINTA THERAPEUTICS
- Tetraphase Pharmaceuticals, Inc.
- Theravance Biopharma
- WOCKHARDT
- Entasis therapeutics
- Paratek Pharmaceuticals
- Inc., Seres Therapeutics
- AbbVie, Inc.,
- Merck & Co. Inc.
- and Pfizer, Inc.
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Antibiotic Resistance Industry News
- In February 2018, FDA approved AVYCAZ of AbbVie, Inc for the patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. This product launch helped the company to strengthen their portfolio and boost their revenue.
- In November 2019, Allergan plc, which is now a part of AbbVie, Inc. received the Qualified Infectious Disease Product (QIDP) designation and fast track designation for ATM-AVI (Aztreonam and Avibactam) for antibiotic-resistant gram-negative infections from U.S. FDA. This helped the company to enhance their position in global market.
The antibiotic resistance market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
Market Size, By Disease
- Complicated urinary tract infections
- Complicated intra-abdominal infections
- Bloodstream infection
- Acute bacterial skin and skin-structure infection
- Community-acquired bacterial pneumonia
- Clostridium difficile infections
- Hospital-acquired bacterial pneumonia
Market Size, By Pathogen
- E. coli
- K. pneumoniae
- P. aeruginosa
- S. aureus
- Baumannii
- S. pneumoniae
- H. influenzae
- C. difficile
- E. faecium
Market Size, By Drug Class
- Oxazolidinones
- Cephalosporin
- Lipoglycopeptides
- Combination therapies
- Tetracyclines
- Other drug classes
Market Size, By Mechanism of Action
- Cell wall synthesis inhibitors
- Protein synthesis inhibitors
- DNA synthesis inhibitors
- RNA synthesis inhibitors
- Other mechanism of actions
Market Size, By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Switzerland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy